Orthocell (ASX:OCC) has confirmed it’s sold its first units of collagen-based bone repair product Striate+ in Canada through distro partner BioHorizons. The move effectively represents a further expansion for the company into another western market after reported success in Australia, the US, EU, and Uk. In July, the company noted it had clocked record revenue. As in other markets, Orthocell’s sales strategy in Canada is targeting the dental market where Striate+ has been shown to receive the most enthusiasm. Health Canada greenlit sales back in July. Orthocell on Friday pointed to a recent po…
